CARsgen Therapeutics(02171.HK): CT0596 Secures NMPA IND Approval for Treatment of R/R MM
NewTimeSpace News: On August 4, 2026, CARsgen Therapeutics(02171.HK) announced that CT0596 has been granted IND approval by the NMPA for the treatment of patients with relapsed/refractory multiple myeloma.
According to the announcement, CT0596 is currently under evaluation via investigator-initiated trials (IIT) in relapsed/refractory multiple myeloma or plasma cell leukaemia. The Company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CARsgen Therapeutics (02171.HK) CT041 Postoperative Adjuvant Therapy Study Results Accepted for ESMO 2026 Poster Presentation
- E Fund CSI HK Equities Information Technology Integration ETF (159196) Sees Fund Shares Increase by Nearly 100 Million Units Over Past 3 Months; Institutions Point Out Global Market Share of Domestic Models May Further Increase
- CHINA-HONGKONG PHOTO PRODUCTS HOLDINGS(01123.HK): Proposed Appointment of Chow Siu Hei as Independent Non-executive Director
- HUAJIN INTL(02738.HK): 52 Judicial Freezing Records Imposed on Equity Interests of Subsidiaries; Company States Daily Operations Unaffected
